Barbara Pistilli

Villejuif, 94805, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 167 publications

Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer.

Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer.

Journal: Tumori
Published: July 31, 2026

Diversity, equity, and inclusion as scientific rigor: progress during challenging times.

Diversity, equity, and inclusion as scientific rigor: progress during challenging times.

Journal: JNCI cancer spectrum
Published: June 08, 2026

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 04, 2026

How artificial intelligence applied to digital pathology could guide treatment personalization in breast cancer.

How artificial intelligence applied to digital pathology could guide treatment personalization in breast cancer.

Journal: ESMO real world data and digital oncology
Published: April 03, 2026

Progress toward personalized management of stage II/III triple negative breast cancer.

Progress toward personalized management of stage II/III triple negative breast cancer.

Journal: Cancer treatment reviews
Published: March 24, 2026

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 24, 2026

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments-A VigiBase Disproportionality Analysis Study.

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments-A VigiBase Disproportionality Analysis Study.

Journal: Clinical pharmacology and therapeutics
Published: March 22, 2026

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.

Journal: ESMO open
Published: March 10, 2026

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 09, 2026

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study.

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study.

Journal: ESMO open
Published: March 02, 2026

Antibody-drug conjugates in precision oncology.

Antibody-drug conjugates in precision oncology.

Journal: Cancer cell
Published: February 12, 2026

Diversity, equity, and inclusion as scientific rigor: progress during challenging times.

Diversity, equity, and inclusion as scientific rigor: progress during challenging times.

Journal: Journal of the National Cancer Institute
Published: February 06, 2026
Showing 1-12 of 167

Last Updated: 09/26/2026